IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)- A EUROPEAN-FOCUSED SYSTEMATIC LITERATURE REVIEW OF DISEASE BURDEN
Author(s)
Wiklund I1, Foster T2, Travers K2, Fortea J3, Prior M31United BioSource Corporation, London, United Kingdom, 2United BioSource Corporation, Lexington, MA, USA, 3Laboratorios Almirall S.A., Barcelona, Spain
OBJECTIVES: To explore disease burden, economic impact, treatment landscape and unmet medical needs in patients with IBS-C METHODS: We conducted a review of MEDLINE- and EMBASE-indexed and `grey’ literature (citeable material that is often not published in peer-reviewed, indexed medical journals, e.g.,web-based international treatment guidelines) published in the last decade (January 2000 to December 2010) pertaining to the epidemiological, clinical, economic, and humanistic impact of IBS-C with a European country focus (France, Germany, Italy, Spain, UK). RESULTS: Altogether 885 unique studies were identified; 106 were included in the analysis. Among patients with IBS, the prevalence estimates of IBS-C range from 24% to 44%. Comorbid conditions such as personality and psychological traits and stress, are common. Patients with IBS-C have lower health-related quality of life (HRQoL) compared with the general population (18 studies); treatment of IBS-C can improve HRQoL. The European societal cost of IBS-C is largely unknown; no European cost-of-illness (COI) studies were identified specifically on IBS-C. In the absence of European data, US data show IBS-C to be cost-intensive. Two cost analyses demonstrated the substantial societal impact of IBS-C, with adult patients experiencing reduced productivity at work or through work absenteeism (mean number of days off work annually: 8.5 to 21.6 days) due to severe, disruptive symptoms. European and local IBS treatment guidelines (where available) offer similar diagnostic/management recommendations; however, IBS-C treatment varies by country. Current monotherapy options for treating IBS-C are suboptimal. 5-HT4 agonists have been evaluated for IBS-C; however, they have been associated with ischaemic colitis or a lack of substantial benefit in IBS-C versus placebo. CONCLUSIONS: Our literature search indicates a lack of monotherapy treatment options to adequately manage IBS-C patients, and the need for European focussed burden of disease and COI studies, to address the evidence gaps identified in this systematic literature search.
Conference/Value in Health Info
2011-11, ISPOR Europe 2011, Madrid, Spain
Value in Health, Vol. 14, No. 7 (November 2011)
Code
PGI5
Topic
Epidemiology & Public Health
Disease
Gastrointestinal Disorders